Concise review: Erythroid versus myeloid lineage commitment: Regulating the master regulators

Stem Cells

Volumn 31, Issue 7, 2013, Pages 1237-1244

  Wolff, Linda ^a   Humeniuk, Rita ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Acute leukemia; Differentiation; Erythroid differentiation; Hematopoietic progenitors; Myeloid cells; Signal transduction; Transcription factors

Indexed keywords

DNA METHYLTRANSFERASE 3A; ERYTHROPOIETIN; FLT3 LIGAND; FLUOROURACIL; LENTIVIRUS VECTOR; MEMBRANE ANTIGEN; PHENYLHYDRAZINE; RETROVIRUS VECTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR PU 1;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BINDING SITE; BONE MARROW CELL; CANCER PROGNOSIS; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; CELL STRESS; CELL SURVIVAL; CHRONIC MYELOMONOCYTIC LEUKEMIA; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DNA BINDING; DNA METHYLATION; ERYTHROCYTE; ERYTHROID CELL; ERYTHROLEUKEMIA; ERYTHROPOIESIS; GENETIC TRANSCRIPTION; GRANULOCYTE; HEMATOLOGIC DISEASE; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; MACROPHAGE; MAMMAL CELL; MEGAKARYOCYTE; MYELODYSPLASTIC SYNDROME; MYELOID DENDRITIC CELL; NEOPLASM; NEUTROPHIL; NONHUMAN; PROTEIN DEGRADATION; PROTEIN TARGETING; REPRESSOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; ZEBRA FISH;

ACUTE LEUKEMIA; DIFFERENTIATION; ERYTHROID DIFFERENTIATION; HEMATOPOIETIC PROGENITORS; MYELOID CELLS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

ANIMALS; CELL DIFFERENTIATION; CELL LINEAGE; ERYTHROID CELLS; HUMANS; MYELOID CELLS;

EID: 84879893899     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1379     Document Type: Article

References (112)

1. Seita J, Weissman IL. Hematopoietic stem cell: Self-renewal versus differentiation. Wiley Interdiscip Rev Syst Biol Med 2010;2:640-653.
2. Adolfsson J, Mansson R, Buza-Vidas N et al. Identification of Flt3 lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. Cell 2005; 121:295-306.
3. Laslo P, Spooner CJ, Warmflash A et al. Multilineage transcriptional priming and determination of alternate hematopoietic cell fates. Cell 2006;126:755-766.
4. Hu M, Krause D, Greaves M et al. Multilineage gene expression precedes commitment in the hemopoietic system. Genes Dev 1997;11: 774-785.
5. Pina C, Fugazza C, Tipping AJ et al. Inferring rules of lineage commitment in haematopoiesis. Nat Cell Biol 2012;14:287-294.
6. Friedman AD. Transcriptional regulation of granulocyte and monocyte development. Oncogene 2002;21:3377-3390.
7. Scott LM, Civin CI, Rorth P et al. A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells. Blood 1992;80:1725-1735.
8. Klemsz MJ, McKercher SR, Celada A et al. The macrophage and B cell-specific transcription factor PU.1 is related to the ets oncogene. Cell 1990;61:113-124.
9. Scott EW, Simon MC, Anastasi J et al. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 1994;265:1573-1577.
10. McKercher SR, Torbett BE, Anderson KL et al. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J 1996;15:5647-5658.
11. Dakic A, Metcalf D, Di Rago L et al. PU.1 regulates the commitment of adult hematopoietic progenitors and restricts granulopoiesis. J Exp Med 2005;201:1487-1502.
12. Iwasaki H, Somoza C, Shigematsu H et al. Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem cells and their differentiation. Blood 2005;106:1590-1600.
13. Zhang P, Iwasaki-Arai J, Iwasaki H et al. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. Immunity 2004;21:853-863.
14. Xie H, Ye M, Feng R et al. Stepwise reprogramming of B cells into macrophages. Cell 2004;117:663-676.
15. Chen H, Ray-Gallet D, Zhang P et al. PU.1 (Spi-1) autoregulates its expression in myeloid cells. Oncogene 1995;11:1549-1560.
16. Wang X, Scott E, Sawyers CL et al. C/EBPalpha bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts. Blood 1999;94:560-571.
17. Iwasaki H, Mizuno S, Arinobu Y et al. The order of expression of transcription factors directs hierarchical specification of hematopoietic lineages. Genes Dev 2006;20:3010-3021.
18. Dahl R, Walsh JC, Lancki D et al. Regulation of macrophage and neutrophil cell fates by the PU.1:C/EBPalpha ratio and granulocyte colony-stimulating factor. Nat Immunol 2003;4:1029-1036.
19. Laslo P, Pongubala JM, Lancki DW et al. Gene regulatory networks directing myeloid and lymphoid cell fates within the immune system. Semin Immunol 2008;20:228-235.
20. Patient RK, McGhee JD. The GATA family (vertebrates and invertebrates). Curr Opin Genet Dev 2002;12:416-422.
21. Heicklen-Klein A, McReynolds LJ, Evans T. Using the zebrafish model to study GATA transcription factors. Semin Cell Dev Biol 2005;16:95-106.
22. Suzuki N, Suwabe N, Ohneda O et al. Identification and characterization of 2 types of erythroid progenitors that express GATA-1 at distinct levels. Blood 2003;102:3575-3583.
23. Pevny L, Simon MC, Robertson E et al. Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1. Nature 1991;349:257-260.
24. Pevny L, Lin CS, D'Agati V et al. Development of hematopoietic cells lacking transcription factor GATA-1. Development 1995;121: 163-172.
25. Fujiwara Y, Browne CP, Cunniff K et al. Arrested development of embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1. Proc Natl Acad Sci USA 1996;93:12355-12358.
26. Ferreira R, Ohneda K, Yamamoto M et al. GATA1 function, a paradigm for transcription factors in hematopoiesis. Mol Cell Biol 2005; 25:1215-1227.
27. Cantor AB, Orkin SH. Transcriptional regulation of erythropoiesis: An affair involving multiple partners. Oncogene 2002;21:3368-3376.
28. Hattangadi SM, Wong P, Zhang L et al. From stem cell to red cell: Regulation of erythropoiesis at multiple levels by multiple proteins, RNAs, and chromatin modifications. Blood 2011;118:6258-6268.
29. Kerenyi MA, Orkin SH. Networking erythropoiesis. J Exp Med 2010;207:2537-2541.
30. Cheng Y, Wu W, Kumar SA et al. Erythroid GATA1 function revealed by genome-wide analysis of transcription factor occupancy, histone modifications, and mRNA expression. Genome Res 2009;19: 2172-2184.
31. Fujiwara T, O'Geen H, Keles S et al. Discovering hematopoietic mechanisms through genome-wide analysis of GATA factor chromatin occupancy. Mol Cell 2009;36:667-681.
32. Soler E, Andrieu-Soler C, de Boer E et al. The genome-wide dynamics of the binding of Ldb1 complexes during erythroid differentiation. Genes Dev 2010;24:277-289.
33. Yu M, Riva L, Xie H et al. Insights into GATA-1-mediated gene activation versus repression via genome-wide chromatin occupancy analysis. Mol Cell 2009;36:682-695.
34. Tripic T, Deng W, Cheng Y et al. SCL and associated proteins distinguish active from repressive GATA transcription factor complexes. Blood 2009;113:2191-2201.
35. Kassouf MT, Hughes JR, Taylor S et al. Genome-wide identification of TAL1's functional targets: Insights into its mechanisms of action in primary erythroid cells. Genome Res 2010;20:1064-1083.
36. Hodge D, Coghill E, Keys J et al. A global role for EKLF in definitive and primitive erythropoiesis. Blood 2006;107:3359-3370.
37. Tallack MR, Whitington T, Yuen WS et al. A global role for KLF1 in erythropoiesis revealed by ChIP-seq in primary erythroid cells. Genome Res 2010;20:1052-1063.
38. Rodriguez P, Bonte E, Krijgsveld J et al. GATA-1 forms distinct activating and repressive complexes in erythroid cells. EMBO J 2005;24:2354-2366.
39. Saleque S, Kim J, Rooke HM et al. Epigenetic regulation of hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors CoREST and LSD1. Mol Cell 2007;27:562-572.
40. Hong W, Nakazawa M, Chen YY et al. FOG-1 recruits the NuRD repressor complex to mediate transcriptional repression by GATA-1. EMBO J 2005;24:2367-2378.
41. Miccio A, Blobel GA. Role of the GATA-1/FOG-1/NuRD pathway in the expression of human beta-like globin genes. Mol Cell Biol 2010;30:3460-3470.
42. Miccio A, Wang Y, Hong W et al. NuRD mediates activating and repressive functions of GATA-1 and FOG-1 during blood development. EMBO J 2010;29:442-456.
43. Bai X, Kim J, Yang Z et al. TIF1gamma controls erythroid cell fate by regulating transcription elongation. Cell 2010;142:133-143.
44. Burda P, Laslo P, Stopka T. The role of PU.1 and GATA-1 transcription factors during normal and leukemogenic hematopoiesis. Leukemia 2010;24:1249-1257.
45. Mancini E, Sanjuan-Pla A, Luciani L et al. FOG-1 and GATA-1 act sequentially to specify definitive megakaryocytic and erythroid progenitors. EMBO J 2012;31:351-365.
46. Kulessa H, Frampton J, Graf T. GATA-1 reprograms avian myelomonocytic cell lines into eosinophils, thromboblasts, and erythroblasts. Genes Dev 1995;9:1250-1262.
47. Yamaguchi Y, Zon LI, Ackerman SJ et al. Forced GATA-1 expression in the murine myeloid cell line M1: Induction of c-Mpl expression and megakaryocytic/erythroid differentiation. Blood 1998;91: 450-457.
48. Moreau-Gachelin F, Tavitian A, Tambourin P. Spi-1 is a putative oncogene in virally induced murine erythroleukaemias. Nature 1988; 331:277-280.
49. Moreau-Gachelin F, Wendling F, Molina T et al. Spi-1/PU.1 transgenic mice develop multistep erythroleukemias. Mol Cell Biol 1996; 16:2453-2463.
50. Choe KS, Radparvar F, Matushansky I et al. Reversal of tumorigenicity and the block to differentiation in erythroleukemia cells by GATA-1. Cancer Res 2003;63:6363-6369.
51. Rao G, Rekhtman N, Cheng G et al. Deregulated expression of the PU.1 transcription factor blocks murine erythroleukemia cell terminal differentiation. Oncogene 1997;14:123-131.
52. Nerlov C, Graf T. PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors. Genes Dev 1998;12: 2403-2412.
53. Heyworth C, Pearson S, May G et al. Transcription factor-mediated lineage switching reveals plasticity in primary committed progenitor cells. EMBO J 2002;21:3770-3781.
54. Galloway JL, Wingert RA, Thisse C et al. Loss of gata1 but not gata2 converts erythropoiesis to myelopoiesis in zebrafish embryos. Dev Cell 2005;8:109-116.
55. Rhodes J, Hagen A, Hsu K et al. Interplay of pu.1 and gata1 determines myelo-erythroid progenitor cell fate in zebrafish. Dev Cell 2005;8:97-108.
56. Rekhtman N, Choe KS, Matushansky I et al. PU.1 and pRB interact and cooperate to repress GATA-1 and block erythroid differentiation. Mol Cell Biol 2003;23:7460-7474.
57. Stopka T, Amanatullah DF, Papetti M et al. PU.1 inhibits the erythroid program by binding to GATA-1 on DNA and creating a repressive chromatin structure. EMBO J 2005;24:3712-3723.
58. Behre G, Whitmarsh AJ, Coghlan MP et al. c-Jun is a JNK-independent coactivator of the PU.1 transcription factor. J Biol Chem 1999;274:4939-4946.
59. Zhang P, Behre G, Pan J et al. Negative cross-talk between hematopoietic regulators: GATA proteins repress PU. 1. Proc Natl Acad Sci USA 1999;96:8705-8710.
60. Rosu-Myles M, Taylor BJ, Wolff L. Loss of the tumor suppressor p15Ink4b enhances myeloid progenitor formation from common myeloid progenitors. Exp Hematol 2007;35:394-406.
61. Bies J, Sramko M, Fares J et al. Myeloid-specific inactivation of p15Ink4b results in monocytosis and predisposition to myeloid leukemia. Blood 2010;116:979-987.
62. Humeniuk R, Rosu-Myles M, Fares J et al. The role of tumor suppressor p15Ink4b in the regulation of hematopoietic progenitor cell fate. Blood Cancer J 2013;2:e99.
63. Fares J, Koller R, Humeniuk R et al. The tumor suppressor p15Ink4b regulates the differentiation and maturation of conventional dendritic cells. Blood 2012;119:5005-5015.
64. Pal S, Cantor AB, Johnson KD et al. Coregulator-dependent facilitation of chromatin occupancy by GATA-1. Proc Natl Acad Sci USA 2004;101:980-985.
65. Anguita E, Hughes J, Heyworth C et al. Globin gene activation during haemopoiesis is driven by protein complexes nucleated by GATA-1 and GATA-2. EMBO J 2004;23:2841-2852.
66. Bresnick EH, Martowicz ML, Pal S et al. Developmental control via GATA factor interplay at chromatin domains. J Cell Physiol 2005; 205:1-9.
67. Lurie LJ, Boyer ME, Grass JA et al. Differential GATA factor stabilities: Implications for chromatin occupancy by structurally similar transcription factors. Biochemistry 2008;47:859-869.
68. Dore LC, Chlon TM, Brown CD et al. Chromatin occupancy analysis reveals genome-wide GATA factor switching during hematopoiesis. Blood 2012;119:3724-3733.
69. Towatari M, May GE, Marais R et al. Regulation of GATA-2 phosphorylation by mitogen-activated protein kinase and interleukin-3.
70. Grass JA, Boyer ME, Pal S et al. GATA-1-dependent transcriptional repression of GATA-2 via disruption of positive autoregulation and domain-wide chromatin remodeling. Proc Natl Acad Sci USA 2003; 100:8811-8816.
71. Grass JA, Jing H, Kim SI et al. Distinct functions of dispersed GATA factor complexes at an endogenous gene locus. Mol Cell Biol 2006;26:7056-7067.
72. Weiss MJ, Keller G, Orkin SH. Novel insights into erythroid development revealed through in vitro differentiation of GATA-1 embryonic stem cells. Genes Dev 1994;8:1184-1197.
73. Rodrigues NP, Boyd AS, Fugazza C et al. GATA-2 regulates granulocyte- macrophage progenitor cell function. Blood 2008;112:4862-4873.
74. Dore LC, Chlon TM, Brown CD et al. Chromatin occupancy analysis reveals genome-wide GATA factor switching during hematopoiesis. Blood 2012;119:3724-3733.
75. Monteiro R, Pouget C, Patient R. The gata1/pu.1 lineage fate paradigm varies between blood populations and is modulated by tif1- gamma. EMBO J 2011;30:1093-1103.
76. Lau CI, Outram SV, Saldana JI et al. Regulation of murine normal and stress-induced erythropoiesis by Desert Hedgehog (Dhh). Blood 2012;119:4741-4751.
77. Sarrazin S, Sieweke M. Integration of cytokine and transcription factor signals in hematopoietic stem cell commitment. Semin Immunol 2011;23:326-334.
78. Stanley ER. Lineage commitment: Cytokines instruct, At last! Cell Stem Cell 2009;5:234-236.
79. Sarrazin S, Mossadegh-Keller N, Fukao T et al. MafB restricts MCSF- dependent myeloid commitment divisions of hematopoietic stem cells. Cell 2009;138:300-313.
80. Mikkelsen TS, Ku M, Jaffe DB et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 2007;448: 553-560.
81. Ji H, Ehrlich LI, Seita J et al. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 2010;467: 338-342.
82. Shih AH, Abdel-Wahab O, Patel JP et al. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012; 12:599-612.
83. Li Z, Cai X, Cai CL et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011;118:4509-4518.
84. Abdel-Wahab O, Adli M, LaFave LM et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 2012;22:180-193.
85. Herrera-Merchan A, Arranz L, Ligos JM et al. Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. Nat Commun 2012;3:623.
86. Chou RH, Yu YL, Hung MC. The roles of EZH2 in cell lineage commitment. Am J Transl Res 2011;3:243-250.
87. Kheradmand Kia S, Solaimani Kartalaei P, Farahbakhshian E et al. EZH2-dependent chromatin looping controls INK4a and INK4b, but not ARF, during human progenitor cell differentiation and cellular senescence. Epigenetics Chromatin 2009;2:16.
88. Perna F, Gurvich N, Hoya-Arias R et al. Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: Possible role in 20q- polycythemia vera. Blood 2010; 116:2812-2821.
89. Koschmieder S, Rosenbauer F, Steidl U et al. Role of transcription factors C/EBPalpha and PU.1 in normal hematopoiesis and leukemia. Int J Hematol 2005;81:368-377.
90. Khan I, Malinge S, Crispino J. Myeloid leukemia in Down syndrome. Crit Rev Oncog 2011;16:25-36.
91. Wechsler J, Greene M, McDevitt MA et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002;32:148-152.
92. Roy A, Cowan G, Mead AJ et al. Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21. Proc Natl Acad Sci USA 2012;109:17579-17584.
93. Kuhl C, Atzberger A, Iborra F et al. GATA1-mediated megakaryocyte differentiation and growth control can be uncoupled and mapped to different domains in GATA1.
94. Muntean AG, Crispino JD. Differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development. Blood 2005;106:1223-1231.
95. Zhang SJ, Ma LY, Huang QH et al. Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. Proc Natl Acad Sci USA 2008;105:2076-2081.
96. Mueller BU, Pabst T, Osato M et al. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 2002;100:998-1007.
97. Rosenbauer F, Wagner K, Kutok JL et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, Pu1. Nat Genet 2004;36:624-630.
98. Durual S, Rideau A, Ruault-Jungblut S et al. Lentiviral PU.1 overexpression restores differentiation in myeloid leukemic blasts. Leukemia 2007;21:1050-1059.
99. Steidl U, Steidl C, Ebralidze A et al. A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. J Clin Invest 2007;117:2611-2620.
100. Gombart AF, Hofmann WK, Kawano S et al. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood 2002;99:1332-1340.
101. Pabst T, Mueller BU, Zhang P et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/ EBPalpha), in acute myeloid leukemia. Nat Genet 2001;27:263-270.
102. Paz-Priel I, Friedman A. C/EBPalpha dysregulation in AML and ALL. Crit Rev Oncog 2011;16:93-102.
103. Score J, Hidalgo-Curtis C, Jones AV et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/ myeloproliferative neoplasms. Blood 2012;119:1208-1213.
104. Nikoloski G, Langemeijer SM, Kuiper RP et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 2010;42:665-667.
105. Makishima H, Jankowska AM, Tiu RV et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia 2010; 24:1799-1804.
106. Ernst T, Chase AJ, Score J et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010;42:722-726.
107. Saunthararajah Y, Maciejewski J. Polycomb segment myeloid malignancies. Blood 2012;119:1097-1098.
108. Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia- lymphoma cells. Leukemia 1998;12:845-859.
109. Shimamoto T, Ohyashiki JH, Ohyashiki K. Methylation of p15(INK4b) and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia. Leuk Res 2005;29:653-659.
110. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2003;17: 1813-1819.
111. Tien HF, Tang JH, Tsay W et al. Methylation of the p15(INK4B) gene in myelodysplastic syndrome: It can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol 2001;112:148-154.
112. Jiang Y, Dunbar A, Gondek LP et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009; 113:1315-1325.